Is sitaxsentan a safe and efficacious treatment for pulmonary arterial hypertension?
Marius M Hoeper
Correspondence Department of Respiratory Medicine, Hannover Medical School, 30623 Hannover, Germany
Email hoeper.marius@mh-hannover.de
This article has no abstract so we have provided the first paragraph of the full text.
Two decades ago, PAH was considered an untreatable disease. Today, endothelin-receptor antagonists (ERAs) together with prostanoids and phosphodiesterase-5 inhibitors are the mainstays of PAH treatment.1 So far only one ERA, bosentan, has been approved for clinical use, but at least two novel ERAs, sitaxsentan and ambrisentan, are expected to receive approval soon. A brief look into the biology of the endothelin system is required to understand the arguments surrounding the selectivity, superiority, and safety of these agents.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
